APOLLO HOSPITALS ENTERPRISE LIMITED



CIN: L85110TN1979PLC008035

12th February 2021

The Secretary,
Bombay Stock Exchange Ltd (BSE)
Phiroze Jheejheebhoy Towers,
Dalal Street,
Mumbai – 400 001.
Scrip Code – 508869
ISIN INE437A01024

The Secretary,
National Stock Exchange,
Exchange Plaza, 5th Floor
Plot No.C/1, 'G' Block
Bandra – Kurla Complex
Bandra (E)
Mumbai – 400 051.
Scrip Code–
APOLLOHOSP
ISIN INE437A01024

The Manager
The National Stock
Exchange,
Wholesale Debt Market
Exchange Plaza, 5th Floor
Plot No.C/1, 'G' Block
Bandra – Kurla Complex
Bandra (E)
Mumbai – 400 051.
ISIN INE437A07120

Dear Sir,

Sub: Limited Review Report on unaudited financial results for the quarter and nine months ended December 31, 2020 with UDIN.

In continuation of the Company's unaudited financial results for the quarter and nine months ended December 31, 2020 ("the Results") filed with the stock exchanges today, please find attached the auditor's Limited Review Report on the Results, with Unique Document Identification Number ("UDIN").

Kindly take the above in your records.

Thanking you,

Yours faithfully,

For APOLLO HOSPITALS ENTERPRISE LIMITED

L. LAKSHMI NARAYANA REDDY

SR. GENERAL MANAGER - SECETARIAL

■ 1. SECETARIAL

CC : The Secretary, Luxembourg Stock Exchange, B.P. 165,

L-2011 Luxembourg.

Ref : ISIN US0376081065 - Rule 144a GDR ISIN US0376082055 - Reg. S GDR Securities and Exchange Commission Division of Corporation Finance Office of International Corporate Finance 450 Fifth Street, N.W.

Washington, D.C 20549-0302 File No. 82-34893

IS/ISO 9001:2000

Regd. Office:
19, Bishop Gardens,
Raja Annamalaipuram,
Chennai - 600 028.

General Office:
"Ali Towers", III Floor,
#55, Greams Road,
Chennai - 600 006.

Tel : 044 - 28290956 / 3896 / 6681 Telefax : 044 - 2829 0956

Email: investor.relations@apollohospitals.com

Website: www.apollohospitals.com

Chartered Accountants Prestige Trade Tower, Level 19 46, Palace Road, High Grounds Bengaluru – 560 001 Karnataka, India

Tel: +91 80 6188 6000 Fax: +91 80 6188 6011

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF APOLLO HOSPITALS ENTERPRISE LIMITED

- We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of APOLLO HOSPITALS ENTERPRISE LIMITED LIMITED ("the Company"), for the three and nine months ended December 31, 2020 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. We draw your attention to Note 7 to the financial results, which describes Management's assessment of the impact of COVID -19 pandemic on significant uncertainties involved in developing some of the estimates involved in preparation of the financial results including recoverability of receivables, Property, plant & equipment including Capital work in progress and certain investments. Based on information available as of this date, Management believes that no further adjustments are required to the financial results. However, in view of the highly uncertain economic environment, a definitive assessment of the impact is highly dependent upon circumstances as they evolve in future and the actual results may differ from those estimated as at the date of approval of these financial results.

Our conclusion on the Statement is not modified in respect of this matter.

For **DELOITTE HASKINS & SELLS LLP**

Chartered Accountants (Firm's Registration No. 117366W/W-100018)

VIKAS Digitally signed by VIKAS BAGARIA Date: 2021.02.12 12:51:44 +05'30'

Vikas Bagaria

Partner

(Membership No. 060408) (UDIN: 21060408AAAAAQ4809)

Place: Bengaluru

Date: February 12, 2021

Apollo Hospitais Enterprise Limited

Corporate Identity Number: L85110TN1979PLC008035

Regd, Office: No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu Tel No. 44-28290956, Fax+ 91-44-282 90956, Email : investor.relations@apullohospitals.com

Website: www.apollohospitals.com

Statement of Unaudited Standalone Financial Results for the three and nine months ended December 31, 2020

S18(0.7)	Three months	Preceeding	Corresponding	Year to date	Year to date	Previous year
	ended	Three months	Three months	figures for	figures for	ended
	31/12/2020	ended	ended	current period	previous	31/03/2020
		30/08/2020	31/12/2019	ended 31/12/2020	period ended	
	Unaudited	manufaction	Unaudited	Unaudited	Unaudited	Audited
Income	And, was an included in the state of the sta	***************************************	***************************************	***************************************	***************************************	ALL TO LANGUAGE AND
(a) Revenue from Operations	2,36,701	2,41,445	2,52,950	6,74,298	7,22,228	9,79,443
(b) Other Income	Co	479	301	740	1,169	1,091
Total Income (a + b)	236794*	2,41,924	2,53,251	6,75,038	7,23,397	9,80,534
(a) Cost of Materials Consumed	37,542	36,075	39,760	97,216	1,16,032	1,53,212
(b) Purchase of Story in Trade	1,02,544	1,05,120	058,850	3,14,438	2,71,984	3,75,419
(c) Changes in inventories of stock in trade	(393)	1,450	(3,440)	(12,648)	(9,375)	(10,433)
(d) Employee Benefits Expense	26,898	33,638	39,244	98,213	1,12,622	1,51,918
(e) Finance Costs	7,577	9,715	11,098	27,554	31,859	42,588
(f) Depreciation and emortisation expense	9,178	11,633	12,308	33,455	35,321	48,226
(g) Other Expenses	38,287	40,331	42,867	1,15,919	1,24,274	1,67,803
Total fxperses	2,21,264	2,37,971	2,38,687	6,74,147	6,82,717	9,28,733
3 Profit before Exceptional from and tax (1) - (2)	15,530	3,953	14,564	168	40,680	51,801
4 Exceptional Item (Refer Note 3)	£ :	(309)	,	(109)		16,435
5 Profit before tax (3) + (4)	15,530	3,844	14,564	782	40,680	68,236
6 Tex Expenses					, <u>,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,</u>	1
Current Tax **	585	(1,897)	5,728	(272)	17,270	31,925
Deferred Tax **	4,719	2,489	(639)	2,791	(3,055)	9386
7 Profit (Loss) for the period / year (5) - (6)	10,622	3,252	9,475	(1,037)	26,465	47,025
8 Other Comprehensive Income/ (Expense)						
Nems that will not be reclassified to Profit and Loss			TT-4-2-47			
Remeasurement gains/(losses) on defined benefit plan	(103)	(858)	~	(1,008)	33	147) 2ml
-Tax on above	36	230	43	352	(13)	(40)
Total Other Comprehensive Income/ (Expense)	(67)	(428)	(80)	(959)	2.4	75
9 Total Comprehensive Income/(Expense) for the period (after tax) (7) + (8)	10,555	2,824	9,395	(1,693)	26,489	47,100

For Apollo Hospitals entenprissille.

Schnesta Reday

100

Corporate Identity Number: L85110TN1979PLC008035 Apollo Hospitals Enterprise Limited

Tel No. 44-28290956, Fax+ 91-44-282 90956, Email: investor.relations@apollohospitals.com Regd. Office: No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu

Website: www.apollohospitals.com

Statement of Unaudited Standalone Financial Results for the three and nine months ended December 31, 2020

Partículars	Three months ended 31/12/2020	Preceeding Three months ended 30/09/2020	Corresponding Three months ended 31/12/2019	Year to date figures for current period ended 31/12/2020	Year to date figures for previous period ended 31/12/2019	Previous year ended 31/03/2020
1	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
10 Paid-up equity share capital (Face value Rs.5/- per share) 11 Reserves (excluding Revaluation Reserves)						5,956
12 Net Worth (Refer footnote 1) 13 Paid up Debt Capital						3,85,570
14 Debenture Redemption Reserve 15 Capital Redemption Reserve						12,500
16 Earnings per equity share of Rs.5/- each Basic and Diluted EPS before extraordinary items for the period (Rs.)	* 7.64	*2.34	*6.81	*(0.74)	*19.02	33.80
basic and bridged Erb aree extraordinary refins for the period (KS.)	*7,64	*2.34	*6.81	*(0.74)	*19.0%	33.80
Debt Equity Ratio (Refer footnote 2) Debt Service Coverage Ratio (DSCR) (Refer footnote 3) Interest Service Coverage Ratio (ISCR) (Refer footnote 4)						0.82 2.92 4,27
Additional Information :- Earnings before finance costs, tax, depreciation and amortization, exceptional items (EBITDA) (Refer footnote 5)	32,193	24,712	37,669	61,051	1,06,691	2,57,959

Not annualised

** Current tax and Deferred Tax expense for three and nine months ended December 31, 2020 includes tax of prior year amounting to Rs. 1,550 lakhs

Foot Notes:

1 Networth = Equity Share Capial + Other Equity excluding Capital Reserves, Capital Redemption Reserve and Debenture Redemption Reserve Debt = Long Term Borrowings +Short Term Borrowings+Current Maturities of Long Term Borrowings 2 Debt Equity Ratio

3 Debt Service Coverage Ratio = Profit before interest, depreciation and tax / Interest on loans + Repayment of long term loans during the period Equity = Paid up capital +Other equity excluding Captal Reserve, Capital Redemption Reserve and Debenture Redemption Reserve

4 Interest Service Coverage Ratio = Profit before depreciation, interest on long term loans and tax / Interest on long term loans

5 The company has presented Earnings before Finance costs, Tax, Depreciation, Amortization, Otherspranscented Farabash Rems (EBITDA) aditionally as part of Financial Results.

ASKINS 8.



CHENNAI-17

10 × DELO/

Apollo Hospitals Enterprise Limited Regd. Office: No. 19 Bishop Gardens, Raja Annamalaipuram, Chennal-28, Tamil Nadu

Segment wise Revenue, Results, Segment Assets and Segment Liabilities

State Stat	Particulars	Three months ended	Preceeding Three months	Corresponding Three months	Year to date figures for current	Year to date figures for	Previous year ended
Interdirect		31/12/2020	ended 30,00,000	a1/12/2019	period ended	previous period	31/03/2020
Part Revenue Part Part Revenue Part Revenue Part Revenue Part Revenue Part Part Revenue Part Revenue Part Revenue Part Part Revenue Part Part		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
### Revenue 1,24,072 1,06,264 1,29,712 2,98,579 3,76,699 3,76,699 3,76,699 3,76,699 3,76,711 3,65,694 3,46,211 3,65,701 3,12,629 3,76,723 3,68,701 3,12,629 3,46,211 3,72,200 3,76,723 3,68 3,46,211 3,72,200 3,76,723 3,68 3,46,211 3,72,200 3,72,							
Secondary 1,24,072 1,05,564 1,23,712 2,58,579 3,46,211 2,46,211 2,56,984 3,46,211 3,50,089 3,60,011 3,60,11 3,60,111	1.Segment Revenue						
Second Services	a) Healthcare Services	1,24,072	1,06,264	1,29,712	2,98,579	3,76,089	4,97,466
### Substitution	b) Retail Pharmacy	010	040'66	1,23,261	2,26,984	3,46,211	4,82,064
State Control Contro	c) Pharmacy Distribution	1,12,629	36,118	9	1,48,747	ě	•
Intersegmental Revenue 2,36,701 2,41,445 2,52,350 6,74,296 7,22,228 5 1,000	SUB - TOTAL	2,36,701	2,41,452	2,52,973	6,74,310	7,22,300	9,79,530
ment Results 2,36,701 2,44,445 2,52,990 6,74,296 7,22,228 5 ment Results ment Results 15,861 4,200 17,842 3,668 50,929 either care Services 15,861 4,200 17,882 11,926 20,441 either care Services 1,561 4,300 7,519 1,169 20,441 either care Services 2,304 1,358 25,364 27,534 31,839 (i) Other un-allocable income, (net of Stip Formar Cost and secte-Segment liabilities 7,570 301 7,40 1,169 (ii) Exceptional litem (Refer Note 3) 1,57,736) 6,57,063 6,57,	Less : Interseamental Revenue		7	23	12	72	88
ment Results 15,861 4,500 17,842 3,668 50,929 subtract Services 15,861 4,500 17,842 3,668 50,929 subtract Services 1,538 1,538 7,519 7,137 1,148 27,705 7,137 state I) because the manage of the manag	Income from Operations	2,36,701	2,41,445	2,52,950	6,74,298	7,22,228	9,79,442
ment Results 15,861 4,500 17,842 3,668 50,929 total Pharmacy In Exercise Interval Sub- Torra 22,014 1,7842 14,926 20,441 total Pharmacy In Exercise Interval Sub- Torra 22,014 1,298 22,705 1,135 (i) Fhance Cost (iv) Other un-allocable income, (net of (iv) Other un-allocable (iv) Other u							
Secretary Secr	2. Segment Results					000	000
Second State Seco	a) Healthcare Services	15,861	4,500	17,842		676,05	087-40
1,556 25,364 27,705 31,859 31	b) Retail Pharmacy	đ	6,730	7,519		20,441	710,82
Sub- TOTAL 23,014 13,188 25,361 27,705 71,370 (i) Finance Cost of the combined be income, (net of ii) Finance Cost (iii) Finance Financ	c) Pharmacy Distribution	7,153	1,958	40	9,111		100 00
(i) Finance Cost (net of 7,577 9,715 11,098 27,554 31,859 (n) Enance Cost (net of 93 480 301 27,554 31,859 (n) Cuter un-allocate in term (neter Note 3) 15,530 3,844 14,564 782 40,680 (note) (SUB - TOTAL	23,014	13,188	25,361		71,370	93,297
	Less ; (i) Finance Cost	7,577	6,715	11,098		31,859	885,588
(III) Exceptional Item (Refer Note 3) (109) - (109) - (109) - (109) - (109) - (109) - (109) - (109) - (109) - (109) - (109) - (109) - (108)	Add: (ii) Other un-allocable income, (net of	93	480	301		1,169	160,1
(Loss) Exploration (Construction) (1,58,230) 3,844 14,564 792 40,680 (Loss) Exploration (Loss) Italian in assets—Segment liabilities (6,67,063) (6,67,063) (6,67,063) (6,67,063) (6,87,404) Assets—Segment liabilities (1,57,736) (1,54,217) (1,54,217) (1,54,216) (1,54,216) At all Pharmacy atail Pharmacy Attabilities (1,04,578) (1,64,578) (1,64,578) (1,64,578) At Liabilities (1,44,905) (1,44,905) (1,44,905) (1,44,905) (1,39,840) At Seets (1,44,905) (1,44,905) (1,44,905) (1,44,905) (1,44,905) (1,39,840) At Seets (1,44,905) (1,44,905) (1,44,905) (1,44,905) (1,44,905) (1,44,905) (1,44,905) (1,59,322) At Liabilities (1,44,905) (1,44,905) (1,44,905) (1,44,905) (1,44,905) (1,44,905) (1,39,840) At Seets (1,44,905) (1,44,905) (1,44,905) (1,44,905) (1,44,905) (1,44,905) (1,44,905) (1,44,905) (1,44,905)<	xpenditure)		(109)		(109)	1.0	16,435
ital employed ant assets-Segment liabilities 6,67,063 6,95,243 6,87,404 6,67,063 6,97,404 and tassets-Segment liabilities (1,58,378) (1,58,378) (1,54,217) (1,54,216) nt Liabilities (1,54,217) (1,54,217) (1,54,216) (1,64,578) nt Liabilities (1,04,578) (1,04,578) (1,04,578) nt Liabilities (1,44,905) (1,44,905) (1,44,905) (1,39,840) natiocated (1,44,905) (3,43,248) (3,43,248) (3,43,248) (3,43,248) natiocated (1,44,905) (3,43,248) (3,43,248) (3,43,248) (3,43,248) (3,43,248) nullesilities 3,93,333 3,93,333 3,93,333 3,93,333 3,93,333 conder construction 27,843 27,843 47,232		15.530	3,844		782	40,680	68,236
### assets-Segment liabilities ### assets-Segment liabilities ### assets-Segment liabilities #### assets-Segment liabilities ####################################	FIGURE (ECOS) DESCRIPTION						
## Assets nt Liabilities stail Pharmacy nt Assets nt Liabilities n	3. Capital employed Segment assets-Segment liabilities						
nt Assets nt Liabilities nt Liabilit	a) Healthcare Services *		Charle Control				
atail Pharmacy (1,57,736) (1,54,217) (1,54,217) (1,54,216) (1,54,216) stail Pharmacy It Assets 1,94,240 1,94,240 1,94,240 1,94,240 int Assets int Labilities (1,04,578) (1,04,578) (1,04,578) (1,04,578) int Labilities (33,222) (27,451) (27,451) (33,222) (33,222) int Labilities (3,43,248) (3,43,248) (3,43,248) (3,43,577) (3,43,577) at Assets (1,44,905) (3,43,248) (3,43,577) (3,43,577) (3,43,577) (3,43,577) cludes Capital employed in various hospital 27,843 25,460 47,232 27,843 47,232 cunder construction 27,843 25,460 47,232 27,843 47,232	Segment Assets	6,67,063					
stail Pharmacy 1,94,240 1,94,240 1,94,240 Int Assets (1,04,578) (1,04,578) (1,04,578) Int Liabilities 33,222 (27,451) 74,565 (33,222) Int Liabilities 1,44,905 1,44,905 1,44,905 1,39,840 Int Liabilities 3,93,537 3,82,758 3,80,539 3,98,539 Int Liabilities 3,93,333 3,80,539 3,98,539 Int Liabilities 3,93,333 3,80,539 3,98,539 Int Liabilities 3,93,333 3,93,333 3,98,539 Int Liabilities 3,93,333 3,98,539 3,98,539 Int Liabilities 3,93,333 3,93,333 3,98,539 Int Liabilities 3,93,333 3,93,333 3,93,333 3,98,539 Int Liabilities 3,93,333 3,93,333 3,93,333 3,98,539 3,98,539 Int Liabilities 3,93,333 3,93,333 3,93,333 3,93,333 3,98,539 Int Liabilities 3,93,333 3,93,333 3,93,333 3,98,539	Segment Liabilities	(1,57,736)					
nt Assets it Liabilities it	b) Retail Pharmacy					0,000	טטג צטט כ
retriabilities (1,04,370) 74,565 (27,451) (33,222) (1,39,840)<	Segment Assets	•		1,94,240		(1 04 578)	(1.12.755
armacy Distribution 87,900 74,565 - 87,900 - nt Liabilities (27,451) - (33,222) - (33,222) nat Liabilities (3,4,905) 1,44,905 1,39,840 1,39,840 1,39,840 1,39,840 nt Liabilities (3,15,577) (3,43,248) (3,82,151) (3,15,577) (3,82,151) nt Liabilities 3,93,333 3,82,778 3,90,539 3,90,539 cludes Capital employed in various hospital 27,843 25,460 47,232 27,843 47,232 curdes Capital employed in various hospital 27,843 25,460 47,232 27,843 47,232	Segment Liabilities	į.		0/5/201			
nt Assets nt Liabilities a, 93,222) (27,451) 1,44,905 1,44,905 (3,45,77) (3,43,248) 1,39,840 1,44,905 (3,15,77) (3,48,15,77) (3,88,16,77) (3,88	c) Pharmacy Distribution				1	- 4	89
nt Liabilities (27,451) (27,451) (33,222) (27,451) (33,222) (33,222) (27,451) (33,222) (33,22	Segment Assets	87,900			D08,18		
net located not Assets 1,44,905 1,44,905 1,39,840 1,39,840 1,39,840 1,39,840 1,39,840 1,39,840 1,39,840 1,39,840 1,39,840 1,39,840 1,39,84,577 1,39,840 1,39,840 1,39,840 1,39,840 1,39,840 1,39,840 1,39,840 1,39,840 1,39,840 1,39,840 1,39,840 1,39,840 1,39,840 1,39,840 1,39,840 1,39,840 1,39,840 1,39,84,537 1,39,84,537 1,39,84,539 3,80,539 3,80,539 3,80,539 3,80,539 3,90,539	Segment Liabilities	(33,222)			(32,444)		R
nt Assets nt Labilities nt Labilities nt Labilities at Capital employed in various hospital cunder construction Labilities at Capital employed in various hospital condex Capital employed in various hospital employed in various h	d) Unaliocated						1 31 978
nt Labolities 3,93,333 3,82,778 3,60,538 3,93,333 3,80,539 3,53,333 cludes Capital employed in various hospital 27,843 25,460 47,232 27,843 47,232	Segment Assets	1,44,905					
cudes Capital amployed in various hospital 27,843 25,460 47,232 27,843 47,232 47,232 27,843 47,232	Total	3.93.333	3.82.778			3,80,539	3,98,855
s under construction 27,843 25,460 47,232 27,843 47,232 47,232 27,843 47,232 27,843 47,232	cludes Capital employed in various						
		27,843	25,460			47,232	22,653
		OUT IN HOSPITALS	S ENTERPRISE LI				

Suneeta Reddy Managing Director



NOTES:

- The unaudited standalone financial results of Apollo Hospitals Enterprise Limited ("the Company") for the three and nine months ended December 31, 2020 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on February 11, 2021 and February 12, 2021 respectively and have been subjected to limited review by the statutory auditors.
- 2. The Company completed a Qualified Institutional Equity placement in January 2021, allotting an additional 46,59,498 equity shares at a price of Rs 2,511 per share (face value Rs 5/- each) aggregating to a sum of Rs 116,999.99 lakhs pursuant to the approval accorded by the members through Postal Ballot to raise equity proceeds upto a sum of Rs 150,000 lakhs.
- 3. The Scheme of Arrangement ('the Scheme') for transfer of front-end retail pharmacy business included in the standalone pharmacy segment ('Divestment Business') to Apollo Pharmacies Limited ('APL' or 'Transferee Company'), a wholly owned subsidiary of Apollo Medicals Private Limited ('AMPL') was effective September 1, 2020 ("the effective date").

Consequently, retail pharmacy segment as presented in these financial results, include transactions of the divestment business till the effective date. Post the disposal of the divestment business, the Company has identified Pharmacy Distribution as a new segment with effect from September 1, 2020. The Company thereafter has identified Heathcare and Pharmacy Distribution as its operating and reportable segments. Healthcare segment represents hospitals and hospital based pharmacies. Pharmacy distribution segment represents the business of procurement and distribution of pharmaceutical, fast moving consumer goods (FMCG) and private label products.

The figures for the three and nine months ended December 31, 2020 are not comparable with the figures for the preceding three months ended September 30, 2020, corresponding three months ended December 31, 2019 and the year to date figures for the previous period ended December 31, 2019.

- 4. On 7th January 2021, the Company completed the acquisition of an 1% additional stake in Medics International Lifesciences Limited ("Medics") which runs a 330 bedded hospital in Lucknow. Consequently, Medics will become a subsidiary of the Company with effect from the date of acquisition and no adjustment for the same has been considered in the results for the current period.
- 5. The proposed acquisition of an additional 50% stake in Apollo Gleneagles Hospital Ltd, Kolkata is yet to be completed pending closure of certain formalities. Consequent to the execution of the Share Purchase Agreement between the Company, Gleneagles Development Pte Ltd and Apollo Gleneagles Hospital Limited, the Company has executed a Second Amendment Agreement extending the Long Stop Date to 28th February, 2021 for consummating the transaction. No effect of this acquisition has therefore been given in these financial results.

CHENNAI-17

FOR APOLLO HOSPITALS ENTERPRISE LTD.

Suneeta Ready Managing Director

- 6. The Board of Directors through a circular resolution, approved the revised proposal in compliance with Section 233 of the Companies Act, 2013 to proceed with an application to the Regional Director, Southern Region, Ministry of Corporate Affairs for approving the Scheme of Merger of the following wholly owned subsidiary companies with the Company, subject to completion of necessary formalities and obtaining requisite approvals instead of filing applications with NCLT seeking dispensation of convening shareholders / creditors meetings of the Company:
 - o Apollo Home Healthcare (India) Limited and
 - Western Hospitals Corporation Private Limited
- 7. The Management has considered the possible effects if any that may result from the pandemic relating to COVID-19 on recoverability of receivables, Property, plant & equipment including Capital work in progress and certain investments. The Company has considered internal and external information up to the date of approval of these financial results. Based on the current indicators of future economic conditions, the Company expects to recover the carrying amount of these assets. The actual outcome of these assumptions and estimates may vary in future due to the impact of the pandemic. The Company will continue to monitor any material changes to future economic conditions and the consequent impact on its business, if any, and any significant impact of these changes would be recognized in the financial results as and when these material changes to economic conditions arise.
- 8. The listed non-convertible debentures of the Company aggregating to Rs. 20,000 lakhs as at December 31, 2020 are secured by way of a charge of the Company's properties and the asset cover thereof exceeds hundred percent of the principal amount of the said debentures.
- 9. The aforesaid financial results are also available on the Company's website (www.apollohospitals.com).

For APOLLO HOSPITALS ENTERPRISE LIMITED

Place: Chennai

Date: February 12, 2021

Dr. Prathap C Reddy Executive Chairman

CHENNAI-17

FOR APOLLO, HOSPITALS ENTERPRISE LTD.

Sunceta Ready Managing Director

Chartered Accountants Prestige Trade Tower, Level 19 46, Palace Road, High Grounds Bengaluru – 560 001 Karnataka, India

Tel: +91 80 6188 6000 Fax: +91 80 6188 6011

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF APOLLO HOSPITALS ENTERPRISE LIMITED

- 1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of APOLLO HOSPITALS ENTERPRISE LIMITED ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net loss after tax and total comprehensive loss (net) of its associates and joint ventures for the three months ended December 31, 2020 and its share of net profit after tax and total comprehensive income for the nine months ended December 31, 2020 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

Name of the Company	Relationship
Apollo Hospitals Enterprise Limited	Parent
Apollo Home Healthcare (India) Limited	Subsidiary
Apollo Home Healthcare Limited	Subsidiary
AB Medical Centres Limited	Subsidiary
Samudra Health Care Enterprises Limited	Subsidiary
Imperial Hospitals & Research Centre Limited	Subsidiary
Apollo Hospitals (UK) Limited	Subsidiary
Apollo Health and Lifestyle Limited (AHLL)	Subsidiary
Alliance Dental Care Limited	Subsidiary of AHLL
Apollo Dialysis Private Limited	Subsidiary of AHLL
Apollo Sugar Clinics Limited	Subsidiary of AHLL
Apollo Speciality Hospitals Private Limited	Subsidiary of AHLL
AHLL Diagnostics Limited	Subsidiary of AHLL
AHLL Risk Management Private Limited	Subsidiary of AHLL
Apollo Bangalore Cradle Limited	Stepdown Subsidiary of AHLL
Kshema Healthcare Private Limited	Stepdown Subsidiary of AHLL
Surya Fertility Center Private Limited	Stepdown Subsidiary of AHLL
Apollo Nellore Hospital Limited	Subsidiary
Sapein Bio-sciences Private Limited	Subsidiary
Apollo Hospitals International Limited (AHIL)	Subsidiary
Apollo-Amrish Oncology Services Private	Associate of AHIL
Limited	OU AND SAME ASSESSMENT OF THE ADMINISTRATION OF
Apollo CVHF Limited	Subsidiary of AHIL
Western Hospitals Corporation Limited	Subsidiary
Apollo Lavasa Health Corporation Limited	Subsidiary
Apollo Rajshree Hospital private Limited	Subsidiary
Future Parking Private Limited	Subsidiary
Total Health	Subsidiary
Apollo Hospitals Singapore Pte Limited	Subsidiary
Assam Hospitals Limited	Subsidiary
Apollo Medical Private Limited (AMPL)	Associate
Apollo Pharmacy Limited	Subsidiary of AMPL
Apollo Gleneagles Hospitals Limited	Joint venture
Apollo Gleneagles PET-CT private Limited	Joint venture
ApoKos Rehab Private limited	Joint venture
Medics International Lifesciences Limited	Joint Venture
Family Health Plan Insurance (TPA) Limited	Associate
Indraprastha Medical Corporation Limited	Associate
Stemcyte India Therapeutics Private Limited	Associate

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 8 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard

and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

We draw attention to Note 8 to the Statement in respect of proceedings initiated against
the company's subsidiary, Imperial Hospital & Research Centre Limited, by the
Government of Karnataka, as reported by the other auditors of the said subsidiary
company.

Our conclusion on the Statement is not modified in respect of this matter.

7. We draw your attention to Note 7 to the Statement, which describes Management's assessment of the impact of COVID -19 pandemic on significant uncertainties involved in developing some of the estimates involved in preparation of the financial results including recoverability of receivables, Property, plant & equipment including Capital work in progress and certain investments. Based on information available as of this date, Management believes that no further adjustments are required to the financial results. However, in view of the highly uncertain economic environment, a definitive assessment of the impact is highly dependent upon circumstances as they evolve in future and the actual results may differ from those estimated as at the date of approval of these financial results.

Our conclusion on the Statement is not modified in respect of this matter

8. We did not review the interim financial results of 20 subsidiaries included in the consolidated unaudited financial results, whose interim financial results reflect total revenues of Rs. 23,874 lakhs and Rs. 59,739 lakhs for the quarter and nine months ended December 31, 2020 respectively, total net profit after tax of Rs. 2,056 lakhs and Rs. 1,288 lakhs for the quarter and nine months ended December 31, 2020 respectively and total comprehensive income (net) of Rs. 2,094 lakhs and Rs. 1,370 lakhs for the quarter and nine months ended December 31, 2020 respectively, as considered in the Statement. The consolidated unaudited financial results also includes the Group's share of net profit after tax of Rs. 803 lakhs and Rs. 105 lakhs for the quarter and nine months ended December 31, 2020 respectively and Group's share of total comprehensive income (net) of Rs. 801 lakhs and Rs. 143 lakhs for the quarter and nine months ended December 31, 2020 respectively, as considered in the Statement, in respect of 1 joint ventures and 5 associates (including 1 subsidiary of an associate), whose interim financial results have not been reviewed by us. These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, joint ventures and associates, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of this matter.

9. The consolidated unaudited financial results includes the interim financial information of 5 subsidiaries which have not been reviewed by their auditors, whose interim financial information reflect total revenue of Rs. 91 lakhs and Rs. 91 lakhs for the quarter and nine months ended December 31, 2020 respectively, total net loss after tax of Rs. 55 lakhs and Rs. 82 lakhs for the quarter and nine months ended December 31, 2020 respectively and total comprehensive loss (net) of Rs. 55 lakhs and Rs. 82 lakhs for the quarter and nine months ended December 31, 2020 respectively, as considered in the Statement. The consolidated unaudited financial results also includes the Group's share of net loss after tax of Rs. 28 lakhs and Rs. 178 lakhs for the quarter and nine months ended December 31, 2020 respectively and total comprehensive loss (net) of Rs. 28 lakhs and Rs. 178 lakhs for the guarter and nine months months ended December 31, 2020 respectively, as considered in the Statement, in respect of 2 joint venture and 1 associates, based on its interim financial information which have not been reviewed by their auditors. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our Conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the Management.

For **DELOITTE HASKINS & SELLS LLP**

Chartered Accountants (Firm's Registration No. 117366W/W-100018)

VIKAS Digitally signed by VIKAS BAGARIA

BAGARIA Date: 2021.02.12
14:34:30 +05'30'

Vikas Bagaria

Partner (Membership No. 060408) (UDIN: 21060408AAAAAR3774)

Place: Bengaluru

Date: February 12, 2021

Apollo Hospitals Enterprise Limited
Corporate Identity Number: L85110TN1979PLC008035
Regd. Office: No. 19 Bishop Gardens, Raja Annamalaipuram, Chennal - 28, Tamil Nadu
Tel No. 44-28290956, Fax+ 91-44-282 90856, Email: Investor.relations@apollohospitals.com
Website: www.apollohospitals.com

Statement of Unaudited Consolidated Financial Results for the three and nine months ended December 31, 2020

(Rs. in Lakhs)

2,75,984 2,76,072 2,91,174 7,69206 8,32,437 11, 2,563 2,564 2,302 11,23 2,302	binaudited Unaudited 11,24 550	Particulars	Three months ended 31/12/2020	Preceeding three months ended 30/09/2020	Corresponding Three months ended 31/12/2019	Year to date figures for current period ended 31/12/2020	Year to date figures for previous period ended 31/12/2019	Previous year ended 31/03/2020
2,75,984	2,75,984 2,76,072 2,91,174 7,69,206 8,32,437 11,24,256 2,500 2,454 2,202 2,454 2,202 3,454 2,202 3,454 2,202 3,454 3,2437 3,11,24,25 3,12,256 3,16,474 2,756 1,03,356 1,35,35 12,230 1,2,256 3,16,474 2,756 1,2,256 1,37,42 2,230 2,330 2,230 2,230 2,330 2,230 2,230 2,330 2,230 2,230 2,330 2,230 2,230 2,330 2,330 2,230 2,30 2,		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
276534* 2,77,204 2,92,140 7,71,660 8,34,739 11,2 45,894 43,261 46,850 1,16,836 1,36,821 1, (1,03,356 1,05,792 1,457 1,230 1,21,256 1,27,2561 3,742 1,27,256 1,27,256 1,37,742 1,2502 1,25,022 1,4,945 12,502 1,4,945 12,502 1,4,945 12,502 1,4,945 12,502 1,4,945 12,502 1,4,945 12,502 1,4,945 12,502 1,4,945 12,73,263 1,54,473 1,54,530 1,54,473 1,54,530 1,55,44 1,5	45,894 43,261 46,850 1,16,836 1,36,821 1,80 45,894 43,261 46,850 1,16,836 1,36,821 1,80 (596) 1,05,792 98,246 3,16,474 2,75,261 3,79 (596) 1,457 47,230 13,743 1,21,256 1,37,742 53 10,097 14,945 15,731 43,465 1,54,473 1,114,845 1,80 2,59,554 2,73,263 2,72,646 7,75,139 1,54,473 1,114,845 1,80 2,59,554 2,73,263 2,72,646 7,75,139 1,54,473 1,114,845 1,80 2,59,554 2,73,263 2,72,646 7,75,139 1,54,473 1,635 1,93,131 1,635 1,37,335 1,93,131 1,54,43 1,46,41 1,81,534 1,54,431 1,14,50 1,34,45 1,46,41 1,54,44 1,46,41 1,54,44 1,46,41 1,54,44 1,46,41 1,54,44 1,46,41 1,54,44 1,46,41 1,44,55 1,44,55 1,44,44 1	1 Income (a) Revenue from Operations	2,75,984	2,76	2,91,174	7,69,206	8,32,437	11,24,680
45,894 43,261 46,850 1,16,836 1,36,821 1,36,821 1,36,821 1,36,821 1,36,821 1,36,821 1,35,325 1,37,32 1,457 1,256 1,37,42 1,37,42 1,250 1,37,42 1,37,42 1,250 1,37,42 1,37,42 1,250 1,37,42 1,250 1,37,42 1,250 1,37,42 1,250 1,37,42 1,250 1,37,42 1,250 1,37,42 1,250 1,37,42 1,250 1,37,43 1,54,473 1,54,4	ates / joint ventures 1,03,356 1,03,356 1,03,356 1,03,356 1,03,356 1,03,356 1,03,356 1,03,356 1,0,097	Total Income (a + 1)	276534 *	2,77	2,92,140	7,71,660	8,34,739	11,27,377
ates / joint vertures	ates / joint vertures	2 Expenses		e de la companya de l	90	1.16.036	1 36 871	1.80.923
tes / joint vertures 15.54	ates / joint vertures 1,53,6	(a) Cost of Materials Consumed	40,000	43,281	98,030	3.16.474	2.75.261	3,79,667
ates / joint verturess	ates / joint vertures 15,235	(b) Purchases of Stock-in-Trade	05C,CD,L		(3.381)	(12,392)	(6)303)	(10,703)
ates / joint veritures	ates / joint veritures	(C) Changes in inventories of stock-in-trade	357 35	_	47,536	1,21,256	1,37,742	1,85,292
ates / joint veritures	ates / joint vertures	(d) Employee Benefit Expense	10.092		13,743	35,066	39,754	53,277
ates / joint ventures	ates / joint vertures	(e) Findnoe Losts	12,51		15,731	43,465	45,583	61,969
ates / joint ventures 16,980 2,73,263 2,77,646 7,75,178 7,97,052 10,8 16,980 3,941 14,494 (3,518) 37,687 4 (3,518) 37,687 4 (3,518) 37,687 4 (3,518) 37,687 4 (3,518) 37,687 4 (3,518) 37,687 4 (3,518) 37,687 4 (3,518) 37,687 4 (3,518) 37,687 4 (4,518) 3,544 3,618 (4,459) 37,335 (4,444) 18,534 4,641 2,410 (5,11) 2,5147 (3,147) 3,524 (3,14	ates / joint vertures	(1) Deprecation and amorrisation expense	4400	54 423	58.921	1.54,473	1,71,194	2,30,772
ates / joint veritures 1,554 (926) 3,941 14,494 (3,518) 37,687 4 1,554 (926) 36 (1,635) (322) (322) (323) (ates / joint veritures 1,554 (926) 3,941 14,494 (3,518) 37,687 46, 46, 15,534 15,534 15,235 15,335 45, 15,534 15,234 15,234 15,234 15,234 15,234 16,534 17,750 6,046 (444) 2,147 (1,750) 6,046 (444) 2,147 (1,750) 6,046 (444) 2,147 (1,750) 6,046 (3,1312) 2,147 (3,147) 4,641 5,899 8,995 (3,312) 22,220 433	(d) Other Expenses	ARD SEA	2.73.263	2.77,646	7,75,178	7,97,052	10,81,197
x(3) + (4)	x(3)+(4)	3 profit/(Loss) before share of profit in associates / joint ventures	16,980	3,941	14,494	(3,518)	37,687	46,180
x(3) + (4)	x(3)+(4)	and exceptional kems (1) - (2)	-			(1,635)	(352)	(311)
18,534 3,544 14,530 (1,609) 37,335 18,262 477 (1,750) 6,046 (444) 18,262 4,641 2,447 (3,147)	477 (1,750) (5,147) (1,502) (4,44) (4,44) (4,44) (4,44) (3,147) 4,641 2,410 (511) 2,147 (3,147) (3,147) (2,220) (2,220) (4,44)	4 Share of profit (1985) or associates & joint Ventures	18 534	E		(\$,153)	37,335	45,869
18,534 6,560 14,530 (1,609) 37,335 8 477 (1,750) 6,046 (444) 18,262 4,641 2,410 (511) 2,147 3,147	18,534 6,560 14,530 (1,609) 37,335 8 477 (1,750) 6,046 (444) 18,262 4,641 2,410 (511) 2,147 (3,147) 13,416 5,899 8,995 (3,312) 22,220	S Profit (LOSS) Detore exceptional Item and take 12, 11, 12, 11, 12, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13		3.544	,	3,544		19,830
477 (1,750) 6,046 (444) 18,262 4,641 2,410 (511) 2,147	477 (1,750) 6,046 (444) 18,262 4,641 2,410 (511) 2,147 (3,147) 13,416 5,899 8,995 (3,312) 22,220	2 Profit / Lare Kelef Note 3)	18,534	6,560	14,530	(1,609)	37,335	669'59
4,641 (511) (5,147) (3,147) (3,147)	4,641 (5.11) (5.147) (3,147) (3,147) (3,147) (3,147) (3,147) (3,147) (3,147) (4,14) (4	8 Tax Expenses				(444)		חכל כו
000 00 00 00 00 00 00 00 00 00 00 00 00	13,416 5,899 8,995 (3,312) 22,220	Current Tax**	477			2.147		9,799
42 44E 5,33.2.	22/22	Deferred Tax**	1404 E+		200.8	(3,312)	22,220	43,180

LLP * SINE CHENNAI-17) TE HASKINS & SE

FOR APOLL OMOSPITALS ENTERPRISE LTD. Suneeta Reddy Managing Director Apollo Hospitals Enterprise Limited
Corporate Identity Number: L85110TN1979PLC008035
Regd. Office: No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu
Tel No. 44-28290956, Fax+ 91-44-282 90956, Email: investor.relations@apollohospitals.com
Website: www.apollohospitals.com

Statement of Unaudited Consolidated Financial Results for the three and nine months ended December 31, 2020

Previous year ended 31/03/2020	Audited	(126)	77	(60)	43,120	45,494	(56)	45,438	6,956	32.70
Previor enc 31/03	Aud									-
Year to date figures for previous period ended 31/12/2019	Unaudited	(733)	229	(504)	21,716	23,558 (1,338)	(311)	23,247 (1,530)		*16.93
Year to date figures for current period ended 31/12/2020	Unaudited	(824)	288	(836)	(3,848)	(1,749)	(561)	(2,310) (1,538)		*(1.26)
Corresponding Three months ended 31/12/2019	Unaudited	(717)	122	(38)	8,900	9,214 (219)	(97)	9,117		* * 6.62
Preceeding three months ended 30/09/2020	Unaudited	(537)	188	(320)	5,549	6,027	(361)	5,665 (118)		* * * * * * *
Three months ended 31/12/2020	Unaudited	(47)	16	(31)	13,384	13.043	(44)	13,000		00 e s
Particulars		10 Other Comprehensive Income / (Expense) Items that will not be reclassified to Profit or Loss Remeasurement gains / (losses) on defined benefit plan Equity instruments through other comprehensive income	Tax on above	Total Other Comprehensive Income/ (Expense)	11 Total Comprehensive Income / (Expense) for the period (after tax)	Profit / (Loss) for the period attributable to: Owners of the parent Non-controlling interest	Other Comprehensive Income/ (Expense) for the period attributable to: Owners of the parent Non-controlling interest	Total Comprehensive Income / (Expense) for the period attributable to: Owners of the parent Non-controlling interest	12 Paid-up equity share capital (Face value Rs.5/- per share) Reserves (excluding Revaluation Reserves)	13 Earnings per equity share of Rs.5/- each Basic and Diluted EPS before extraordinary items for the period (Rs.) Basic and Diluted EPS after extraordinary items for the period (Re.)

*Not annualised

** Current lax and Deferred Tax expense for the three and nine months ended December 31, 2020 includes tax of prior year amounting to Rs.1,550 lakhs

CHENNAI-17

CHENAI-17

CHENNAI-17

CHENNAI-17

CHENNAI-17

CHENNAI-17

CHENNAI

FOI APOLLO HOSPITALS ENTERPRISE LTD.

Apollo Hospitals Enterprise Limited Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennal-28, Tamil Nadu

Consolidated Segment wise Revenue, Results, Segment Assets and Segment Liabilities

(Rs. In Lakhs)

Particulars	Three months ended 31/12/2020	Preceeding three months ended 30/09/2020	Corresponding Three months ended 31/12/2019	Year to date figures for current period ended 31/12/2020	Year to date figures for previous period ended 31/12/2019	Previous year ended 31/03/2020
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. Segment Revenue						
a) Healthcare Services	1,44,281	1,24,270	1,49,786	3,48,077	4,34,913	5,75,036
b) Refail Pharmacy	9	99,070	1,23,261	2,26,984	3,46,211	4,82,064
	19,732	17,152	18,537	47,127	52,903	969'69
d) Others	107	103	111	310	328	438
e) Pharmacy Distribution	1,12,629	36,118		1,48,747		3
SUB - TOTAL	2,76,749	2,76,712	2,91,695	7,71,245	8,34,355	11,27,174
ese · Intercenmental Revenue	764	640	521	2,039	1,918	2,494
income from Operations	2,75,984	2,76,072	2,91,174	7,69,206	8,32,437	11,24,680
2. Segment Results					000	200 OF
a) Healthcare Services	18,867	6,404	19,794	7,137		4770/
b) Retail Pharmacy	•	6,729	7,519	14,926	200	29,017
c) Clinics	597	13	(9)	Ξ	E	(2,186)
d) Others	(06)	(99)	(36)	(237)	(246)	(315)
e) Pharmacy Distribution	7,153	1,958	4	9,111		
SUB - TOTAL	26,527	15,038	27,271	29,094	76,139	96,760
Less: (1) Finance Cost	10,097	12,230	13,743	35,066	39,754	53,277
Add: (ii) Other un-allocable income, (net of	550	1,132	966	2,454	2,302	2,697
expenditure)	c			3,544	(₩	19,830
Profit (il nee) Reform Tax	16,980		14,494	26	37,687	68,010

CHENNAI-17

CHENAI-17

CHENNAI-17

CHENNAI-17

CHENNAI-17

CHENNAI-17

CHENNAI

FOR APOLL ONOSPITALS ENTERPRISE LTD.
Sunesta Ready
Managing Director

Apollo Hospitals Enterprise Limited Regd. Office: No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai-28, Tamil Nadu

Consolidated Segment wise Revenue, Results, Segment Assets and Segment Liabilities

						(Rs. in Lakhs)
	Three months	Preceeding	Corresponding	Year to date	Year to date	Previous year
	31/12/2020	ended	ended	rigures for current period	previous period	31/03/2020
rannous		30/09/2020	31/12/2019	ended 31/12/2020	ended 31/12/2019	
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
3. Capital employed						
a) Healthcare Services *		0	1	6	5	2000
Segment Assets Segment Liabilities	(2,44,539)	(2,38,831)	(2,31,958)	(2,44,539)	(2,31,958)	(2,28,645)
b) Retail Pharmacy						
Segment Assets			1,94,240	1	1,94,240	2,05,500
Segment Liabilties			(1,04,578)	:00	(1,04,578)	(1,12,755)
c) Clinics						
Segment Assets	96,425	81,680	82,435	96,425	82,435	82,317
Segment Liabilties	(68,051)	(64,616)	(60,261)	(68,051)	(60.261)	(63,665)
d) Others						
Segment Assets	4,670	4,708	4,790	4,670	4,790	4,774
Segment Liabilties	(1,998)	(1,958)	(1,818)	(1,998)	(1,818)	(1,948)
e) Pharmacy Distribution						
Segment Assets	87,900	74,565	š	87,900	\$ (0)	
Segment Liabilities	(33,222)	(27,451)	1	(33,222)	(N)	
f) Unallocated						
Segment Assets	81,004	81,874	86,979	81,004	626'98	81,078
Segment Liabilties	(3,50,723)	(3,84,507)	(4,29,016)	(3,50,723)	(4,29,016)	(3,92,895)
Total	3,30,427	3,13,571	3,14,342	3,30,427	3,14,342	3,33,941
* Includes Capital employed in various hospital projects under construction	23.164	26.568	47,650	23.164	47,650	23,561



FOR APOLI O HOSPITALS ENTERPRÍSELTO.

Wanaging Director

NOTES:

- 1. The unaudited consolidated financial results of Apollo Hospitals Enterprise Limited ("the Group") and its subsidiaries (referred to as "Group") and its share of profit/loss of its associates and joint ventures, for the three and nine months ended December 31, 2020 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on February 11, 2021 and February 12, 2021, respectively and have been subjected to limited review by the statutory auditors.
- 2. The Company completed a Qualified Institutional Equity placement in January 2021, allotting an additional 46,59,498 equity shares at a price of Rs 2,511 per share (face value Rs 5/- each) aggregating to a sum of Rs 116,999.99 lakhs pursuant to the approval accorded by the members through Postal Ballot to raise equity proceeds upto a sum of Rs 150,000 lakhs.
- 3. The Scheme of Arrangement ('the Scheme') for transfer of front-end retail pharmacy business included in the standalone pharmacy segment ('divestment business') to Apollo Pharmacies Limited ('APL' or 'Transferee Company'), a wholly owned subsidiary of Apollo Medicals Private Limited ('AMPL') for an overall cash consideration of Rs.52,780 lakhs was approved by the National Company Law Tribunal vide their Order dated August 3, 2020.

Pursuant to the Scheme becoming effective, the Company invested Rs.3,650 lakhs and its ownership interest in AMPL changed to 25.50%, resulting in loss of control with effect from September 1, 2020. Net gain associated with the loss of control of Rs. 3,544 lakhs has been included under Exceptional items..

Retail pharmacy segment as presented in these financial results, include transactions of the divestment business till the effective date. Post the disposal of the divestment business, the Company has identified Pharmacy Distribution as a new segment with effect from September 1, 2020. The Company thereafter has identified Healthcare, Pharmacy Distribution, Clinics and others as its operating and reportable segments. Healthcare segment represents hospitals and hospital based pharmacies. Pharmacy distribution segment represents the business of procurement and distribution of pharmaceutical, fast moving consumer goods (FMCG) and private label products. Clinics segment includes clinics and diagnostics and Others segment includes revenue, assets and liabilities of components not engaged in any of the above segments.

The figures for the three and nine months ended December 31, 2020 are not comparable with the figures for the preceding three months ended September 30, 2020, corresponding three months ended December 31, 2019 and the year to date figures for the previous period ended December 31, 2019.

4. On 7th January 2021, the Company completed the acquisition of an 1% additional stake in Medics International Lifesciences Limited ("Medics") which runs a 330 bedded hospital in Lucknow. Consequently, Medics will become a subsidiary of the Company with effect from the date of acquisition and no adjustment for the same has been considered in the results for the current period.

CHENNAI-17

For APOLLO HOSPITAL S ENTERPRISE LTD.

Suneeta Ready Managing Director

- 5. The proposed acquisition of an additional 50% stake in Apollo Gleneagles Hospital Ltd, Kolkata is yet to be completed pending closure of certain formalities. Consequent to the execution of the Share Purchase Agreement between the Company, Gleneagles Development Pte Ltd and Apollo Gleneagles Hospital Limited, the Company has executed a Second Amendment Agreement extending the Long Stop Date to 28th February, 2021 for consummating the transaction. No effect of this acquisition has therefore been given in these financial results.
- 6. The Board of Directors through a circular resolution, approved the revised proposal in compliance with Section 233 of the Companies Act, 2013 to proceed with an application to the Regional Director, Southern Region, Ministry of Corporate Affairs for approving the Scheme of Merger of the following wholly owned subsidiary companies with the Company, subject to completion of necessary formalities and obtaining requisite approvals instead of filing applications with NCLT seeking dispensation of convening shareholders / creditors meetings of the Company:
 - o Apollo Home Healthcare (India) Limited and
 - Western Hospitals Corporation Private Limited
- 7. The Management has considered the possible effects if any that may result from the pandemic relating to COVID-19 on recoverability of receivables, Property, plant & equipment including Capital work in progress and certain investments. The Group has considered internal and external information up to the date of approval of these financial results. Based on the current indicators of future economic conditions, the Group expects to recover the carrying amount of these assets. The actual outcome of these assumptions and estimates may vary in future due to the impact of the pandemic. The Group will continue to monitor any material changes to future economic conditions and the consequent impact on its business, if any, and any significant impact of these changes would be recognized in the financial results as and when these material changes to economic conditions arise.
- 8. The proceedings initiated against Imperial Hospitals and Research Centre Limited, a subsidiary company, by the Government of Karnataka alleging, non-compliance of certain conditions associated with the allotment of land, has been stayed by the Honourable High Court of Karnataka on April 27, 2018. Based on legal opinion, the management is of the opinion that it has adequate grounds to demonstrate compliance with applicable conditions and therefore the proceedings are not sustainable. There have been no further developments during this quarter.
- 9. The listed non-convertible debentures of the Company aggregating to Rs. 20,000 lakhs as at December 31, 2020 are secured by way of a charge of the Company's properties and the asset cover thereof exceeds hundred percent of the principal amount of the said debentures.
- 10. The aforesaid financial results are also available on the Company's website (www.apollohospitals.com)

For APOLLO HOSPITALS ENTERPRISE LIMITED

Place: Chennai

CHENNAI-17

Date: February 12, 2021

Dr. Prathap C Reddy **Executive Chairman**

FOR APOLYO HOSPITALS ENTERPRISE LTD.

uneeta Redd

Managing Director